GO:0001512 dihydronicotinamide riboside quinone reductase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001512 describes the enzymatic activity that transfers electrons from the reduced cofactor NRH (1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide) to a quinone, producing a hydroquinone and NR+.
• The activity is classically associated with NQO2 (NRH:quinone oxidoreductase 2), a flavoprotein that uses NRH rather than NAD(P)H as its preferred electron donor.
• NQO2 is distinct from NQO1: NQO1 uses NAD(P)H, is inhibited by dicoumarol, and is a well-known protective enzyme, whereas NQO2 uses NRH and is not inhibited by dicoumarol.
• NQO2 expression and activity vary widely across human populations and during development, with an exon 3 single-nucleotide polymorphism reducing activity in some individuals.
• NQO2 can bioactivate certain antitumor quinones such as RH1, making this activity relevant to cancer pharmacology and drug design.
• Studying GO:0001512 requires combining enzyme kinetics, quinone substrate profiling, and genetic models to separate NQO2-specific effects from those of other reductases.
Description
GO:0001512, dihydronicotinamide riboside quinone reductase activity, is a molecular function that catalyzes the reduction of a quinone to a hydroquinone using 1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide (NRH) as the electron donor. This activity is best known as the catalytic function of NQO2 (NRH:quinone oxidoreductase 2), a cytosolic flavoprotein that is structurally related to but functionally distinct from NQO1. Because quinones are ubiquitous in cellular metabolism and in xenobiotic exposure, enzymes that reduce them play important roles in redox balance, detoxification, and drug metabolism. Researchers study GO:0001512 to understand how cells handle quinone stress, how NQO2 contributes to cancer and other diseases, and how this activity can be exploited or inhibited therapeutically. The unusual cosubstrate specificity of NQO2, which prefers NRH over NAD(P)H, has been conserved throughout amniotes, suggesting a non-redundant cellular function. This article summarizes the definition, mechanism, key genes, disease links, and experimental approaches for studying GO:0001512.
dihydronicotinamide riboside quinone reductase activity At A Glance
| GO ID | GO:0001512 |
|---|---|
| GO term | dihydronicotinamide riboside quinone reductase activity |
| Ontology | molecular_function |
| Synonym | NQO2 activity; NRH:quinone oxidoreductase 2 activity; QR2 activity; quinone reductase 2 activity; ribosyldihydronicotinamide dehydrogenase (quinone) activity |
| Major function | Reduction of quinones to hydroquinones using NRH as the electron donor |
| Representative enzyme | NQO2 (NRH:quinone oxidoreductase 2), a cytosolic flavoprotein |
| Cofactor | Flavin adenine dinucleotide (FAD) |
| Electron donor | NRH (1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide) |
| Inhibitor profile | Not inhibited by dicoumarol, unlike NQO1 |
What Is GO:0001512?
In simple terms, GO:0001512 is the activity that uses NRH to turn a quinone into a hydroquinone. According to the QuickGO definition, it catalyzes the reaction: 1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + a quinone = 1-(beta-D-ribofuranosyl)nicotinamide + a hydroquinone. This activity is also known as NQO2 activity, NRH:quinone oxidoreductase 2 activity, QR2 activity, and ribosyldihydronicotinamide dehydrogenase (quinone) activity. It is a molecular_function term in the Gene Ontology and is distinct from NAD(P)H-dependent quinone reductases such as NQO1.
Why Is dihydronicotinamide riboside quinone reductase activity Important in Cell Biology?
GO:0001512 matters because it defines a quinone-reducing activity that operates through an unusual NRH-dependent mechanism, linking cellular redox chemistry to detoxification, drug activation, and disease. NQO2, the main enzyme carrying this activity, is expressed in many tissues and its activity varies between individuals due to genetic polymorphisms, which can influence susceptibility to cancer and responses to quinone-based drugs. Understanding this activity helps researchers interpret redox biology, design NQO2-selective inhibitors or substrates, and build better models of quinone-related toxicity and therapy.
• Defines a distinct quinone reductase activity that uses NRH instead of NAD(P)H, separating it from NQO1 biology.
• Supports cellular defense against quinone-induced oxidative stress by converting quinones to hydroquinones.
• Contributes to the bioactivation of antitumor quinones such as RH1, affecting drug efficacy and toxicity.
• Shows population variability and developmental changes in human liver, with an exon 3 SNP reducing NQO2 activity.
• Is conserved across amniotes, suggesting an important, non-redundant cellular role for the NRH-dependent activity.
• Has been linked to cancer progression, including oral squamous cell carcinoma, through NQO2-related pathways.
• Provides a target for chemical probes and inhibitors that can distinguish NQO2 from other reductases.
• Helps explain inter-individual differences in drug metabolism and quinone toxicity in cancer therapy.
What Happens During dihydronicotinamide riboside quinone reductase activity?
Substrate binding and electron transfer
In simple terms: The enzyme grabs NRH and a quinone, then passes electrons from NRH to the quinone.
The reaction begins when NQO2 binds its electron donor, NRH, and a quinone substrate. NRH donates a hydride equivalent to the FAD cofactor, and the reduced FAD then transfers electrons to the quinone, converting it to a hydroquinone. This two-electron reduction avoids the formation of semiquinone radicals, which is a key feature of the catalytic mechanism.
Quinone reduction and product release
In simple terms: The quinone becomes a hydroquinone, and the products leave the enzyme.
After electron transfer, the quinone is reduced to a hydroquinone, and NRH is oxidized to NR+ (1-(beta-D-ribofuranosyl)nicotinamide). The hydroquinone product is released, allowing the enzyme to cycle again. The catalytic efficiency depends on the quinone substrate, and NQO2 can reduce a range of quinones with different rates.
Cofactor and cosubstrate specificity
In simple terms: NQO2 uses FAD and prefers NRH over NADH or NADPH.
NQO2 is a flavoprotein that uses FAD as a prosthetic group. Unlike NQO1, which uses NAD(P)H, NQO2 shows a strong preference for NRH as the electron donor. This unusual cosubstrate specificity is conserved throughout amniotes, implying that NRH availability may regulate the activity in cells.
Inhibition and regulation
In simple terms: Some chemicals can block NQO2, but the classic NQO1 inhibitor dicoumarol does not.
NQO2 activity is not inhibited by dicoumarol, which distinguishes it from NQO1. Other compounds, such as certain flavonoids and synthetic inhibitors, can modulate NQO2 activity. The enzyme's activity can also be influenced by genetic polymorphisms, such as an exon 3 single-nucleotide polymorphism that reduces NQO2 activity in some individuals.
Key Genes Involved in GO:0001512 dihydronicotinamide riboside quinone reductase activity
The following genes and proteins are directly or indirectly involved in GO:0001512 and its biological context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NQO2 | Encodes NRH:quinone oxidoreductase 2, the main enzyme with GO:0001512 activity | Central to studies of NRH-dependent quinone reduction, drug metabolism, and cancer |
| NQO1 | Encodes NAD(P)H:quinone oxidoreductase 1, a related but distinct quinone reductase | Used as a comparison to distinguish NQO2-specific effects and as a protective enzyme in cardiovascular disease |
| FAD | Flavin adenine dinucleotide cofactor required for NQO2 catalysis | Essential for enzyme activity; studied in reconstitution and kinetic assays |
| NRH | Reduced nicotinamide riboside, the preferred electron donor for NQO2 | Key cosubstrate whose availability may regulate GO:0001512 in cells |
| HOXA11-AS | Long non-coding RNA that may regulate NQO2 expression in cancer | Studied in oral squamous cell carcinoma metastasis and NQO2 axis |
| TP53 | Tumor suppressor often mutated in cancers where NQO2 is studied | Context for understanding NQO2 roles in cancer cell survival and drug response |
| KEAP1 | Regulator of NRF2, which controls antioxidant and quinone reductase genes | Links NQO2 biology to oxidative stress response pathways |
| NFE2L2 (NRF2) | Transcription factor regulating antioxidant and detoxification genes | May influence NQO2 expression and quinone detoxification |
| CYP450 enzymes | Phase I enzymes that can generate quinones from xenobiotics | Relevant to quinone substrate availability for NQO2 |
| GSTs | Glutathione S-transferases that conjugate quinones | Complementary detoxification pathways to NQO2 |
| UGTs | UDP-glucuronosyltransferases involved in phase II metabolism | Indirectly affect quinone levels and NQO2 substrate load |
| SLC transporters | Membrane transporters that may affect NRH uptake | Potential regulators of intracellular NRH availability for NQO2 |
| NRK1 | Nicotinamide riboside kinase that generates NAD+ from NR | May influence NRH pools and NQO2 activity |
| NNMT | Nicotinamide N-methyltransferase that consumes nicotinamide | Could affect NRH/NR balance and NQO2 function |
| PARPs | Poly(ADP-ribose) polymerases that consume NAD+ | Impact cellular NAD+ and NRH metabolism, indirectly affecting NQO2 |
| CD38 | NAD+ glycohydrolase that regulates NAD+ levels | Modulates NAD+ and NRH pools, potentially affecting NQO2 activity |
| SIRT1 | NAD+-dependent deacetylase | Links NAD+ metabolism to NQO2-related redox biology |
| NQO2 SNP variants | Genetic variants such as exon 3 SNP that reduce NQO2 activity | Used in population studies of cancer risk and drug response |
How Is dihydronicotinamide riboside quinone reductase activity Regulated?
GO:0001512 is regulated at multiple levels. The availability of the cosubstrate NRH is a key determinant, as NQO2 requires NRH for activity. Genetic variation, such as an exon 3 single-nucleotide polymorphism in NQO2, can reduce enzyme activity in some individuals. Expression of NQO2 may also be influenced by transcriptional regulators of the antioxidant response, although direct evidence for NRF2 regulation of NQO2 is less clear than for NQO1. Additionally, the long non-coding RNA HOXA11-AS has been implicated in an axis with NQOs that enhances metastatic ability in oral squamous cell carcinoma, suggesting post-transcriptional or indirect regulation.
dihydronicotinamide riboside quinone reductase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NQO2 | Bladder and ovarian cancer; reduced activity with exon 3 SNP | NQO2 knockout or SNP knock-in cancer cell lines |
| NQO2 | Bioactivation of antitumor quinone RH1 | NQO2 overexpression and knockout cells treated with RH1 |
| NQO2 | Oral squamous cell carcinoma metastasis via HOXA11-AS axis | NQO2 knockdown in oral cancer cells |
| NQO1 | Cardiovascular disease and oxidative stress protection | NQO1 knockout mouse models |
| NQO2 | Population variability in drug metabolism | Primary hepatocytes or liver cell models with NQO2 variants |
Cancer and drug response
NQO2 activity has been studied in bladder and ovarian cancer, where lower NRH:quinone oxidoreductase 2 activity was associated with an NQO2 exon 3 single-nucleotide polymorphism. NQO2 can bioactivate the antitumor quinone RH1, contributing to cytotoxicity, which makes GO:0001512 relevant to cancer chemotherapy. In oral squamous cell carcinoma, an axis between the long non-coding RNA HOXA11-AS and NQOs, including NQO2, enhances metastatic ability.
Cardiovascular and oxidative stress
Quinone reductases, including NQO1 and by extension NQO2, have been proposed to play protective roles in cardiovascular diseases and related conditions by reducing quinone-induced oxidative stress. Although much of the evidence focuses on NQO1, the shared chemistry of quinone reduction suggests that GO:0001512 may contribute to cellular defense in cardiovascular contexts.
Population variability and development
Human hepatic NQO2 activity shows ontogeny and population variability, with an exon 3 SNP reducing activity. This variability can influence individual susceptibility to quinone toxicity and drug responses, making GO:0001512 a factor in personalized medicine.
From dihydronicotinamide riboside quinone reductase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does NQO2 knockout reduce quinone reduction in cells? | NQO2 knockout cell line (e.g., CRISPR-Cas9) |
| How does the exon 3 SNP affect NQO2 activity? | Point-mutation knock-in of the SNP in a cell line |
| Can NQO2 overexpression increase RH1 cytotoxicity? | NQO2 overexpression cell model treated with RH1 |
| What is the role of NQO2 in cancer metastasis? | NQO2 knockout or knockdown in oral squamous cell carcinoma cells |
| How does NRH availability regulate NQO2 activity? | Cells with modulated NRH metabolism (e.g., NRK1 overexpression) |
| Can we screen for NQO2-specific inhibitors? | Recombinant NQO2 enzyme assays and cell-based screens |
How to Study the dihydronicotinamide riboside quinone reductase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme activity assay | Quinone reduction rate using NRH | Characterizing NQO2 kinetics and inhibitors |
| CRISPR-Cas9 knockout | Loss of NQO2 function | Testing dependence on GO:0001512 |
| SNP knock-in | Effect of exon 3 SNP on activity | Modeling population variability |
| qPCR/Western blot | NQO2 mRNA and protein levels | Expression studies in tissues and cells |
| Cell viability assay | Cytotoxicity of quinone drugs | Drug response studies with RH1 |
| Recombinant protein purification | Isolated NQO2 for in vitro assays | Structural and mechanistic studies |
| Metabolic profiling | NRH and NAD+ levels | Linking cosubstrate availability to activity |
| RNA interference | Knockdown of NQO2 or related genes | Functional studies in cancer cells |
Enzyme kinetics and substrate profiling
Recombinant NQO2 can be used to measure GO:0001512 activity with various quinone substrates and NRH as the electron donor. Kinetic parameters such as Km and Vmax help compare substrate specificity and inhibitor potency.
Genetic manipulation and knockout models
CRISPR-Cas9 knockout of NQO2 in cell lines allows researchers to test the contribution of GO:0001512 to quinone detoxification, drug response, and oxidative stress. Knock-in of the exon 3 SNP can model population variability.
Expression analysis and polymorphism detection
Quantitative PCR, Western blotting, and genotyping can measure NQO2 expression and identify SNPs that affect activity. These methods help link genotype to enzyme activity in human samples.
Drug response and cytotoxicity assays
Cell viability assays with quinone-based drugs such as RH1 can reveal how NQO2 activity modulates drug efficacy and toxicity. Combining these with NQO2 inhibitors or knockout clarifies the role of GO:0001512.
How CRISPR Can Be Used to Study GO:0001512 dihydronicotinamide riboside quinone reductase activity
Knockout
CRISPR-Cas9 knockout of NQO2 creates cells completely lacking GO:0001512 activity, enabling researchers to test its role in quinone detoxification, drug response, and oxidative stress. Knockout models are essential for distinguishing NQO2 from NQO1 and other reductases.
Point Mutation
Introducing the NQO2 exon 3 single-nucleotide polymorphism via CRISPR point mutation allows study of how this variant reduces enzyme activity and affects drug metabolism or cancer risk. Such models mimic human population variability.
Knock-in
Knock-in of tagged NQO2 (e.g., FLAG or GFP) enables localization, interaction, and activity studies in live cells. This approach helps track GO:0001512 in specific cellular compartments.
Overexpression
CRISPR activation or lentiviral overexpression of NQO2 increases GO:0001512 activity, useful for testing whether higher activity enhances bioactivation of antitumor quinones like RH1 or protects against oxidative stress.
How EDITGENE Supports dihydronicotinamide riboside quinone reductase activity Research
Researchers studying dihydronicotinamide riboside quinone reductase activity-related genes often need to determine whether a candidate gene is causally involved in quinone metabolism, drug response, or disease. EDITGENE provides CRISPR-based cell model services to support these investigations with reproducible, publication-ready models.
Contact EDITGENE today to design your custom CRISPR model for dihydronicotinamide riboside quinone reductase activity research.
Frequently Asked Questions About dihydronicotinamide riboside quinone reductase activity
What is dihydronicotinamide riboside quinone reductase activity?
It is the enzymatic activity defined by GO:0001512 that reduces a quinone to a hydroquinone using NRH as the electron donor, typically carried out by NQO2.
What genes are involved in dihydronicotinamide riboside quinone reductase activity?
The main gene is NQO2, which encodes NRH:quinone oxidoreductase 2. Related genes include NQO1 and metabolic genes affecting NRH availability.
What is the difference between NQO1 and NQO2?
NQO1 uses NAD(P)H and is inhibited by dicoumarol, while NQO2 uses NRH and is not inhibited by dicoumarol.
What is the substrate of NQO2?
NQO2 uses NRH as the electron donor and reduces various quinones to hydroquinones.
How is NQO2 activity measured?
It is measured by enzyme assays monitoring quinone reduction using NRH, often with recombinant NQO2 or cell lysates.
Is NQO2 activity associated with cancer?
Yes, NQO2 activity has been studied in bladder, ovarian, and oral cancers, and it can bioactivate antitumor quinones like RH1.
What is the NQO2 exon 3 SNP?
It is a single-nucleotide polymorphism in NQO2 that is associated with reduced NRH:quinone oxidoreductase 2 activity in some individuals.
Can NQO2 be inhibited?
Yes, NQO2 can be inhibited by certain compounds, but not by dicoumarol, which distinguishes it from NQO1.
Why is NRH important for NQO2?
NRH is the preferred electron donor for NQO2, and its availability can regulate GO:0001512 activity in cells.
How can CRISPR help study NQO2 function?
CRISPR knockout, knock-in, and point mutation models allow researchers to test the specific contribution of NQO2 and its variants to quinone metabolism and disease.
Conclusion
GO:0001512, dihydronicotinamide riboside quinone reductase activity, defines a unique NRH-dependent quinone reduction mechanism primarily carried out by NQO2. Its unusual cosubstrate specificity, population variability, and links to cancer and drug response make it an important target for redox biology and pharmacology. By combining enzyme assays, genetic models, and CRISPR-based approaches, researchers can clarify how this activity contributes to health and disease and develop selective modulators for therapeutic benefit.
References
- 1. Wu K et al.. 1997. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase.. Arch Biochem Biophys 347(2):221-8 PMID: 9367528
- 2. Riches Z et al.. 2017. The ontogeny and population variability of human hepatic dihydronicotinamide riboside:quinone oxidoreductase (NQO2).. J Biochem Mol Toxicol 31(8) PMID: 28346733
- 3. Chen S et al.. 2000. Structure-function studies of DT-diaphorase (NQO1) and NRH: quinone oxidoreductase (NQO2).. Free Radic Biol Med 29(3-4):276-84 PMID: 11035256
- 4. Zhu H et al.. 2012. NAD(P)H: quinone oxidoreductase 1 and its potential protective role in cardiovascular diseases and related conditions.. Cardiovasc Toxicol 12(1):39-45 PMID: 21818552
- 5. Islam F et al.. 2022. The Unusual Cosubstrate Specificity of NQO2: Conservation Throughout the Amniotes and Implications for Cellular Function.. Front Pharmacol 13:838500 PMID: 35517822
- 6. Jamieson D et al.. 2007. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.. Clin Cancer Res 13(5):1584-90 PMID: 17332305
- 7. Nakashima C et al.. 2022. An Axis between the Long Non-Coding RNA HOXA11-AS and NQOs Enhances Metastatic Ability in Oral Squamous Cell Carcinoma.. Int J Mol Sci 23(18) PMID: 36142607
- 8. Yan C et al.. 2008. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).. Mol Pharmacol 74(6):1657-65 PMID: 18794327
